The need for markers and predictors of Rituximab treatment resistance.

Abstract

CD20-specific antibodies show remarkable therapeutic efficacy in B-cell malignancy and autoimmune diseases, but due to the occurrence of a significant treatment resistance, a critical, unmet need for improving B-cell-depleting approaches remains. A CD20 transcript variant (D393-CD20) appears to be associated with Rituximab treatment resistance in malignant B cells, but is lacking in patients with autoimmune dermatoses as shown by Gamonet et al. While CD20-specific factors certainly play a major role in the pathogenesis of Rituximab treatment resistance, the D393-CD2 transcript may greatly facilitate the development of clinical markers for monitoring the therapy in B-cell malignancies and (auto)antibody-mediated diseases. Its association with systemic autoimmune diseases should be therefore explored in further studies.

• Authors: Cassian Sitaru, Jens Thiel
• Journal: Experimental dermatology (Exp Dermatol) Vol. 23 Issue 4 Pg. 236-7 (Apr 2014) ISSN: 1600-0625 [Electronic] Denmark
• PMID: 24450995 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Antigens, CD20
• Biomarkers
• Immunologic Factors
• Rituximab

Topics

• Alternative Splicing
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Antigens, CD20 (metabolism)
• Autoimmune Diseases (drug therapy)
• Biomarkers (metabolism)
• Drug Resistance, Neoplasm
• Humans
• Immunologic Factors (therapeutic use)
• Rituximab
• Skin Diseases (drug therapy)